---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-020970"
form_type: "8-K"
ticker: "ASBP"
cik: "0001847345"
company_name: "Aspire Biopharma Holdings, Inc."
filed_at: "2024-05-22T23:59:59+00:00"
generated_at: "2026-06-01T09:51:06.549907+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# PowerUp enters non-redemption pact; up to 450K shares held, sponsor to transfer shares to preserve trust

## Summary
- Non-redemption agreement with unaffiliated shareholder for up to 450,000 Public Shares at the May 22, 2024 extraordinary general meeting to approve extension.
- Sponsor will transfer 25,000 Founder Shares and 25,000 New Issued Shares (to be issued at business combination close) for each 150,000 non-redeemed shares.
- Agreement aims to increase funds remaining in trust account; extension would push business combination deadline to February 17, 2025.
- Transfer of shares conditioned on approval of extension at meeting and consummation of initial business combination.
- Investor waives redemption rights on the specified shares and agrees not to redeem them in connection with the extension.

## SEC filing metadata
- accession: 0001493152-24-020970
- form_type: 8-K
- ticker: ASBP
- cik: 0001847345
- company_name: Aspire Biopharma Holdings, Inc.
- filed_at: 2024-05-22T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1847345/000149315224020970/0001493152-24-020970-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1847345/000149315224020970/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-020970
- JSON: https://secwatch.observer/filing/0001493152-24-020970.json
- Plain text: https://secwatch.observer/filing/0001493152-24-020970.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.